Dublin, Feb. 27, 2024 (GLOBE NEWSWIRE) -- The "Pre-Eclampsia - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.
This report report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Pre-Eclampsia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
The report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Pre-Eclampsia pipeline landscape is provided which includes the disease overview and Pre-Eclampsia treatment guidelines. The assessment part of the report embraces, in depth Pre-Eclampsia commercial assessment and clinical assessment of the pipeline products under development.
In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pre-Eclampsia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Pre-Eclampsia R&D. The therapies under development are focused on novel approaches to treat/improve Pre-Eclampsia.
Pre-Eclampsia Emerging Drugs Chapters
This segment of the Pre-Eclampsia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Pre-Eclampsia Emerging Drugs
CBP-4888: Comanche Biopharma
CBP-4888 is a fixed-dose combination of two chemically-synthesized, lipid-conjugated small interfering ribonucleic acid (siRNAs) duplex oligonucleotides (siRNA-2283 and siRNA-2519). The investigational therapy is designed to decrease the production of soluble fms-like tyrosine kinase-1 (sFLT1) mRNA isoforms in the placenta. Currently, the drug is in the Phase I stage of its development for the treatment of Preeclampsia.
Pre-Eclampsia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Pre-Eclampsia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pre-Eclampsia drugs.
Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Products have been categorized under various ROAs such as
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
- Molecule Type
Products have been categorized under various Molecule types such as
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
- Product Type
Pre-Eclampsia Report Insights
- Pre-Eclampsia Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Pre-Eclampsia Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Players
- Gmax Biopharm
- Vicore Pharma
- Comanche Biopharma
Key Products
- GMA-312
- C 103
- CBP-4888
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/54k2dq
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
